Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmpire Bluecross Avlayah Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentEmpire BluecrossPolicy CC-0302

    Avlayah (tividenofusp alfa-eknm) Coverage Criteria

    Customize your policy alerts

    Sign up for Empire Bluecross Policy CC-0302 alerts

    Get alerted when Policy CC-0302 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-necessity review and prior authorization for Avlayah in pediatric individuals with Mucopolysaccharidosis II (Hunter syndrome), including initial treatment, continuation therapy, quantity limits, and applicable billing codes. Coverage is limited to neurologic manifestations before advanced neurologic impairment.

    Policy Summary
    PayerEmpire Bluecross
    PolicyAvlayah (tividenofusp alfa-eknm) Coverage Criteria
    Policy CodePolicy CC-0302
    Change TypeNew
    Effective DateJun 23, 2026
    Last ReviewMay 15, 2026
    Next Review DateNot scheduled
    Key ActionSubmit initial and continuation requests for clinical review and prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    <18 yearsMaximum age for initial therapy
    ≥5 kgMinimum weight for initial therapy
    15 mg/kg weeklyAvlayah quantity limit
    3Applicable HCPCS codes

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    E76.1
    Applicable ICD-10-CM diagnosis code
    1Combination-therapy exclusion

    Coverage Criteria

    Initial Therapy

    Initial requests may be approved when all of the following are met.

    Initial therapy

    • Age and weight: Individual is less than 18 years of age and weighs at least 5 kg.Age <18 years; weight ≥5 kg
    • Diagnostic confirmation

      • Enzyme deficiency: Deficiency in iduronate 2-sulfatase enzyme activity measured in fibroblasts or leukocytes combined with normal enzyme activity of another sulfatase, with documentation provided.
      • Genetic confirmation: A pathologic iduronate 2-sulfatase gene mutation, with documentation provided.
    • Indication and neurologic status: Treatment is for neurologic manifestations of MPS II, and the individual does not have advanced neurologic impairment.

    Continuation Therapy

    Continuation requests may be approved when the following criterion is met.

    Continuation response: Documentation is provided that there is clinically significant improvement or stabilization in clinical signs and symptoms of disease compared with the predicted natural-history trajectory of disease.

    Examples include reduction in cerebrospinal fluid heparan sulfate and improvement in neurologic function.

    Not Approved

    Avlayah may not be approved under the following circumstances.

    Noncovered use

    • Combination therapy exclusion: The individual is using Avlayah in combination with Elaprase.
    • Criteria not met or other indication: The applicable criteria are not met, or Avlayah is requested for any other indication.

    Avlayah must not be used in combination with Elaprase. Requests for combination therapy are not approved.

    Avlayah is not approved when the applicable coverage criteria are not met or when treatment is requested for any other indication.

    Coding and Quantity Parameters

    HCPCSHCPCS
    C9399Unclassified drugs or biologicals [when specified as Avlayah (tividenofusp alfa-eknm)]
    J3590Unclassified biologics [when specified as Avlayah (tividenofusp alfa-eknm)]
    S9357Home infusion therapy, enzyme replacement intravenous therapy, (e.g., Imiglucerase); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
    ICD-10 DiagnosisICD-10
    E76.1Mucopolysaccharidosis, type II [Hunter's syndrome]
    Initial-Treatment Age
    Initial-treatment ageLess than 18 years of age
    Initial-Treatment Weight
    Initial-treatment weightAt least 5 kg
    Avlayah Dose Quantity Limit
    Avlayah dose quantity limit15 mg/kg once weekly

    Provider Actions and Review Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Avlayah requests subject to clinical review. Initial requests must satisfy the applicable age, weight, diagnosis, and documentation criteria; continuation requests require documentation of treatment response or stabilization.

    • Initial requests: individual is under 18 years of age and weighs at least 5 kg.
    • Clinical review applies to both initial and continuation requests.
    Documentation Required

    Confirmatory Diagnostic Documentation

    Provide documentation confirming MPS II (Hunter syndrome) through qualifying iduronate 2-sulfatase deficiency or a pathologic iduronate 2-sulfatase gene mutation.

    • Document deficient iduronate 2-sulfatase enzyme activity in fibroblasts or leukocytes, together with normal activity of another sulfatase; or

    Clinical Background

    Mucopolysaccharidosis II (MPS II), also called Hunter syndrome, is an inherited lysosomal storage disease caused by deficient iduronate 2-sulfatase activity. The deficiency leads to progressive accumulation of glycosaminoglycans and may result in respiratory, cardiac, skeletal, neurologic, and ophthalmologic complications.

    Definitions

    Definition
    MucopolysaccharidosisAn inherited metabolic disease caused by deficiency of lysosomal enzymes needed to break down mucopolysaccharides or glycosaminoglycans, leading to progressive accumulation in lysosomes.
    Definition
    MPS II (Hunter syndrome)Mucopolysaccharidosis type II, also called Hunter syndrome, associated with iduronate 2-sulfatase deficiency or a pathologic iduronate 2-sulfatase gene mutation.

    Initial Therapy Criteria

    Initial Therapy

    Initial requests may be approved if all of the following criteria are met.

    Initial therapy

    • Age and weight: Individual is less than 18 years of age and weighs at least 5 kg.Age <18 years; weight ≥5 kg
    • Diagnostic confirmation

      • Enzyme deficiency: Deficiency in iduronate 2-sulfatase enzyme activity measured in fibroblasts or leukocytes combined with normal enzyme activity of another sulfatase, with documentation provided.
      • Genetic confirmation: A pathologic iduronate 2-sulfatase gene mutation, with documentation provided.

    Continuation Criteria

    Continuation Therapy

    Continuation requests may be approved if the following criterion is met.

    Continuation response: Documentation is provided that there is clinically significant improvement or stabilization in clinical signs and symptoms of disease compared with the predicted natural-history trajectory of disease.

    Examples include reduction in cerebrospinal fluid heparan sulfate and improvement in neurologic function.

    Quantity Limits

    Quantity Limit
    Avlayah (tividenofusp alfa-eknm) 150 mg vial15 mg/kg once weekly
    Policy Summary
    PayerEmpire Bluecross
    PolicyAvlayah (tividenofusp alfa-eknm) Coverage Criteria
    Policy CodePolicy CC-0302
    Change TypeNew
    Effective DateJun 23, 2026
    Last ReviewMay 15, 2026
    Next Review DateNot scheduled
    Key ActionSubmit initial and continuation requests for clinical review and prior authorization.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Quantity ParametersProvider Actions and Review RequirementsClinical BackgroundDefinitionsInitial Therapy CriteriaContinuation CriteriaQuantity Limits
  1. Document a pathologic iduronate 2-sulfatase gene mutation.
  2. Documentation Required

    Continuation Response Documentation

    For continuation approval, provide documentation of clinically significant improvement or stabilization in the disease’s clinical signs and symptoms compared with the predicted natural history trajectory.

    • Examples include reduction in cerebrospinal fluid heparan sulfate (HS) or improvement in neurologic function.
    Denial Risk

    Excluded Use or Unmet Criteria

    Approval may be denied when Avlayah is used in combination with Elaprase, when the stated approval criteria are not met, or for any other indication.

    • Combination therapy with Elaprase is not approved.
    • Requests that fail the applicable criteria or are for other indications are not approved.
    Denial Risk

    Neurologic Indication and Impairment Restriction

    Approval requires that Avlayah be requested for the treatment of neurologic manifestations of MPS II (Hunter syndrome) and that the individual does not have advanced neurologic impairment.

    • Requests for non-neurologic manifestations are at risk for denial.
    • Advanced neurologic impairment is an exclusion.
  3. Indication and neurologic status: Treatment is for neurologic manifestations of MPS II, and the individual does not have advanced neurologic impairment.